# Biological Therapy in Treating Patients With Prostate Cancer

> **NCT00002637** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** gene-modified tumor cell vaccine therapy
- **BIOLOGICAL:** recombinant interferon gamma

## Key facts

- **NCT ID:** NCT00002637
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-01
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002637, "Biological Therapy in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*